Revised disclosure for Appointment of Secretarial and Cost Auditors is attached. Please note that there is no appointment/ change in Internal Auditors. The "Internal Auditors" was mentioned ....
Awaiting price reaction for this filing.
Fortis Healthcare's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditors B S R & Co. LLP issuing an unmodified opinion. FY25 standalone revenue from operations rose to ₹1,44,589 lacs (vs ₹1,18,141 lacs in FY24), but net profit dropped sharply to ₹6,379 lacs (vs ₹19,945 lacs) mainly due to an exceptional loss of ₹11,514 lacs from impairment of investments in subsidiaries. The board recommended a final dividend of ₹1 per share (10% on face value of ₹10), subject to shareholder approval. M/s Neelam Gupta & Associates was appointed as Secretarial Auditor for five years (FY26–FY30), and M/s Jitender, Navneet & Co. as Cost Auditor for FY26. The headline notes this is a revised disclosure clarifying there is no change in Internal Auditors. The auditor's report also flags ongoing emphasis-of-matter items related to the legacy SFIO investigation and Supreme Court matters.
Revenue growth is positive, but the sharp fall in full-year net profit due to a large subsidiary investment impairment may weigh on near-term sentiment, while the modest ₹1 dividend offers limited yield. The appointment of new secretarial and cost auditors is routine compliance and not material to shareholders.